C12N 15/907
In mammalian cells
Official title: {in mammalian cells}
C12N15/907 (In mammalian cells) appears on 1,742 US grants and 4,174 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,742
- Published applications
- 4,174
- Assignees
- 1,074
- Inventors
- 5,993
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 9 | 0 |
| 1998 | 7 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 14 | 1 |
| 2002 | 7 | 21 |
| 2003 | 15 | 24 |
| 2004 | 10 | 29 |
| 2005 | 7 | 23 |
| 2006 | 7 | 24 |
| 2007 | 9 | 13 |
| 2008 | 9 | 15 |
| 2009 | 5 | 22 |
| 2010 | 5 | 19 |
| 2011 | 12 | 37 |
| 2012 | 22 | 47 |
| 2013 | 22 | 44 |
| 2014 | 31 | 98 |
| 2015 | 28 | 100 |
| 2016 | 64 | 150 |
| 2017 | 56 | 150 |
| 2018 | 73 | 205 |
| 2019 | 100 | 261 |
| 2020 | 156 | 327 |
| 2021 | 145 | 393 |
| 2022 | 180 | 414 |
| 2023 | 171 | 493 |
| 2024 | 175 | 475 |
| 2025 | 215 | 441 |
| 2026 | 156 | 348 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition for use in treating dystrophic epidermolysis bullosa6 Oct 2026US 12,751,974 B2Osaka University
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014